Article Details

Risk Adjusted Net Present Value: What is the current valuation of Roche's RVT-3101

Retrieved on: 2024-09-08 17:45:17

Tags for this article:

Click the tags to see associated articles and topics

Risk Adjusted Net Present Value: What is the current valuation of Roche's RVT-3101. View article details on hiswai:

Summary

The article describes how GlobalData's business intelligence tools, using risk-adjusted net present value (rNPV) models, provide valuation insights for Roche's monoclonal antibody RVT-3101. These tools aid in capital budgeting and fundamental analysis, adjusting for clinical and market risks.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up